Market: NMS |
Currency: USD
Address: 2265 Upper Middle Road East
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Show more
📈 Cardiol Therapeutics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.05
-
Upside/Downside from Analyst Target:
577.97%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-04-01
-
EPS Estimate:
-0.11
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Cardiol Therapeutics Inc.
| Date | Reported EPS |
|---|
| 2026-03-31 (estimated upcoming) | - |
| 2025-11-13 | -0.12 |
| 2025-08-14 | -0.1 |
| 2025-05-14 | -0.1 |
| 2025-03-31 | -0.09 |
| 2024-11-14 | -0.18 |
| 2024-08-12 | -0.1 |
| 2024-05-14 | -0.14 |
| 2024-04-01 | -0.12 |
| 2023-11-14 | -0.09 |
| 2023-08-10 | -0.12 |
| 2023-05-15 | -0.11 |
| 2023-03-28 | -0.11 |
| 2022-11-10 | -0.13 |
| 2022-08-10 | -0.1 |
| 2022-05-16 | -0.14 |
| 2022-03-22 | -0.11 |
| 2021-08-16 | -0.15 |
| 2021-05-16 | -0.26 |
| 2020-11-12 | -0.13 |
| 2020-05-13 | -0.12 |
| 2020-03-26 | -0.12 |
| 2019-05-08 | -0.13 |
📰 Related News & Research
No related articles found for "cardiol therapeutics".
